Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT05407311 Active, not recruiting - Clinical trials for Biochemical Recurrence of Malignant Neoplasm of Prostate

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

SABRE
Start date: September 19, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.

NCT ID: NCT05370508 Active, not recruiting - Recurrent GBM Clinical Trials

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Start date: February 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this trial are to evaluate the safety, dose-limiting toxicities, maximum tolerated dose (MTD), maximum administered dose (MAD) and recommended Phase 2 dose (RP2D) for future study after a single treatment of SONALA-001 in combination with MRgFUS and to evaluate preliminary efficacy of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device in subjects with progressive or recurrent GBM.

NCT ID: NCT05367687 Active, not recruiting - Clinical trials for Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.

NCT ID: NCT05364450 Active, not recruiting - Breast Cancer Clinical Trials

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

Start date: July 17, 2021
Phase: N/A
Study type: Interventional

Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy compared to Cognitive Behavioral Therapy and enhanced usual care for breast cancer survivors suffering from FCR while examining its cost-effectiveness and the mechanisms by which the intervention may work. Study findings will guide the future care of breast cancer survivors with FCR.

NCT ID: NCT05335993 Active, not recruiting - Peritoneal Cancer Clinical Trials

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Start date: July 25, 2022
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.

NCT ID: NCT05324501 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

MAGIC-G1
Start date: October 19, 2022
Phase: Phase 1
Study type: Interventional

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

NCT ID: NCT05294172 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: June 16, 2022
Phase: Phase 3
Study type: Interventional

The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

NCT ID: NCT05221684 Active, not recruiting - Recurrence Clinical Trials

Lymph Node Ratio as a Predictor for Outcome in Rectal Cancer

Start date: June 9, 2020
Phase:
Study type: Observational

This study aims to evaluate the value of the LNR as a prognostic indicator in patients with rectal cancer who offered total mesorectal excision.

NCT ID: NCT05219734 Active, not recruiting - Cancer Clinical Trials

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

MARIA
Start date: November 29, 2021
Phase:
Study type: Observational

This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.

NCT ID: NCT05212779 Active, not recruiting - Clinical trials for Epithelial Ovarian Cancer

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Start date: October 7, 2022
Phase:
Study type: Observational

Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.